Liste mise à jour le 23 avril 2008

2002 - 01 : Effect of ropinirole on sleep onset : a randomized placebo controlled study in healthy volunteers.
J. Ferreira, M. Galitzky, C. Thalamas, M. Tiberge, J. L. Montastruc, C. Sampaio and O. Rascol
Neurology, 2002, 58, 460-462.

2002 - 02 : A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output : A double-blind, placebo-controlled, fMRI study in healthy subjectfs
I. Loubinoux, J. Pariente, K. Boulanouar, C. Carel, C. Manelfe, O. Rascol, P. Celsis and F. Chollet
Neuroimage, 2002, 15, 26-36.

2002 - 03 : A genome wide scan for familial high myopia suggests a novel locus on chromosome 7q36.
L. Naiglin, C. Gazagne, F. Dallongeville, C. Thalamas, A. Idder, O. Rascol, F. Malecaze and P. Calvas
J Med Genet, 2002, 39, 2, 118-124.

2002 - 04 : In vivo regulation of human skeletal muscle gene expression by thyroid hormone
K. Clement, N. Viguerie, M. Diehn, A. Alizadeh, P. Barbe, C. Thalamas, J. D. Storey, P. O. Brown, G. S. Barsh and D. Langin
Genome Res, 2002, 12, 2, 281-91.

2002 - 05 : Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A doiuble-blind, placebo-controlled, multi-dose study in healthy subjects.
I. Loubinoux, J. Pariente, O. Rascol, P. Celsis and F. Chollet
Neuropsychologia, 2002, 1937, 1-7.

2002 - 06 : Treatment interventions for Parkinson’s disease : an evidence based assessment
O. Rascol, C. G. Goetz, W. Koller, W. Poewe and C. Sampaio
The Lancet, 2002, 359, 1589-1598.

2002 - 07 : Une biothèque en France dans le cadre d’une étude épidémiologique : Comment ? Exemple de l’étude E3N-EPIC
C. Guibout-Peigné, N. Prisse and F. Clavel-Chapelon
Ann Biol Clin, 2002, 60, 3, 293-298.

2002 - 08 : Transmission of group II heteronymous pathways is enhanced in rigid lower limb of de novo patients with Parkinson’s disease
M. Simonetta Moreau, S. Meunier, M. Vidailhet, S. Pol, M. Galitzky and O. Rascol
Brain, 2002, 125, Pt 9, 2125-33.

2002 - 09 : A randomized paired eye comparison of two techniques for treating moderately high myopia : LASIK and artisan phakic lens
F. J. Malecaze, H. Hulin, P. Bierer, P. Fournie, H. Grandjean, C. Thalamas and J. L. Guell
Ophthalmology, 2002, 109, 9, 1622-30.

2002 - 10 : Strenuous but not moderate exercise increases the thrombotic tendency in healthy sedentary male volunteers
Y. Cadroy, F. Pillard, K. S. Sakariassen, C. Thalamas, B. Boneu and D. Riviere
J Appl Physiol, 2002, 93, 3, 829-33.

2002 - 11 : Yohimbine administration prevents over-responsiveness to epinephrine induced by simulated microgravity
M. Berlan, S. Verhaeghe, A. Pavy-Le Traon, C. Thalamas, M. Lafontan, M. A. Marques, J. M. Senard, M. Parent and J. Galitzky
Aviat Space Envir Md, 2002, 73, 8, 735-42.

2002 - 12 : Management of Parkinson’s disease : an evidence-based review
C. Goetz, W. Koller, W. Poewe, O. Rascol and C. Sampaio
Movement Disord, 2002, 17, S4, I.

2002 - 13 : Facteurs pharmacologiques à l’origine des dyskinésies
P. Damier and O. Rascol
Les dyskinésies, 2002, Chapitre 9, 113-121.

2002 - 14 : Facteurs pharmacologiques susceptibles de moduler l’expression des dyskinésies
P. Damier, O. Rascol and J. Micallef
Les dyskinésies (ouvrage), 2002, Chapitre 11, 141-146.

2002 - 15 : Prévention des dyskinésies déterminées par la dopa chez les malades parkinsoniens ? Approches pharmacologiques
J. L. Montastruc and O. Rascol
Les dyskinésies (ouvrage), 2002, Chapitre 12, 151-159.

2002 - 16 : Prise en charge médicamenteuse des dyskinésies dopa-induites dans la maladie de Parkinson
O. Blin, M. Ziegler, A. Benabid and O. Rascol
Les dyskinésies (ouvrage), 2002, Chapitre 14, 183-191.

2002 - 17 : Recent data on the regulation of lipolysis by catecholamines and natriuretic peptides
M. Lafontan, M. Berlan, V. Stich, F. Crampes, D. Riviere, I. De Glisezinski, C. Sengenes and J. Galitzky
Ann Endocrinol (Paris), 2002, 63, 2 Pt 1, 86-90.

2002 - 18 : Enhanced response of the left frontal cortex to slowed down speech in dyslexia : an fMRI study
S. Ruff, D. Cardebat, N. Marie and J. F. Demonet
Brain Imaging, 2002, 13, 10, 1285-1289.

2002 - 19 : Evaluation médico-économique d’une cure thermale à Ussat-Les-Bains dans la maladie de Parkinson
C. Brefel-Courbon, K. Desboeuf, C. Thalamas, M. Galitzky, J. M. Senard, O. Rascol and J. L. Montastruc
La Presse Thermale et Climatique, 2002, 139, 99-108.

2002 - 20 : Dosing with ropinirole in a clinical setting
A. Korczyn, C. Thalamas and C. H. Adler
Acta Neurol Scand, 2002, 106, 4, 200-204.

2002 - 21 : Clinical and genetic studies of families with the tau N279K mutation (FTDP-17)
Y. Tsuboi, M. Baker, M. Hutton, R. J. Uitti, O. Rascol, M. B. Delise, X. Soulages, J. R. Murrell, B. Ghetti, M. Yasuda, O. Komure, S. Kuno, K. Arima, N. Sunohara, T. Kobayashi, Y. Mizuno and Z. K. Wszolek
Neurology, 2002, 59, 1791-1793.

2002 - 22 : Medical treatment of L-dopa-induced dyskinesias
O. Rascol, C. Brefel-Courbon, P. Payoux and J. Ferreira
Mapping the Progress of Alzheimer’s and Parkinson’s disease, 2002, 51, 409-415.

2002 - 23 : Prise en charge des dyskinésies induites par la levodopa
O. Rascol, J. Ferreira, P. Payoux, C. Brefel-Courbon, P. Peran and J. L. Montastruc
Rev Neurol, 2002, 158, 7s117-7s124.

2002 - 24 : Propriétés pharmacodynamiques des agonistes dopaminergiques ? Quelle transférabilité en pratique clinique dans le traitement de la maladie de Parkinson ?
J. L. Montastruc and O. Rascol
La Lettre du Neurologue, 2002, 3, VI, 98-102.

2002 - 25 : Clinical features and disease haplotypes of individuals with the N279K tau gene mutation
Y. Tsubio, R. J. Uitti, M. B. Delisle, J. Ferreira, C. Brefel-Courbon, O. Rascol, B. Ghetti, J. R. Murrell, M. Hutton, M. Baker and Z. K. Wszolek
Arch Neurol, 2002, 59, 943-950.

2002 - 26 : The management of patients with early Parkinson’s disease
O. Rascol, P. Payoux, J. Ferreira and C. Brefel-Courbon
Parkinsonism and related disorders, 2002, 9, 1, 61-67.

2002 - 27 : A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS
M. Clanet, E. W. Radue, L. Kappos, H. P. Hartung, R. Hohlfeld, M. Sanderg-Wollheim, M. F. Kooijmans-Coutinho, E. C. Tsao, A. W. Sandrock and E. I.-a. A. D.-C. S. Investigators
Neurology, 2002, 59, 10, 1507-17.

2002 - 28 : Récupération neurologique post-ischémique (Rehabilitation after stroke)
B. Guiraud-Chaumeil, J. Pariente, J. F. Albucher, I. Loubinoux and F. Chollet
Bull Acad Natl Med, 2002, 186, 6, 1015-1024.

2003 - 01 : Deficit of verb generation in nondemented patients with Parkinson’s disease
P. Peran, O. Rascol, J. F. Demonet, P. Celsis, J. L. Nespoulous, B. Dubois and D. Cardebat
Mov Disord, 2003, 18, 2, 150-156.

2003 - 02 : The management of patients with early Parkinson’s disease
O. Rascol, C. Brefel-Courbon, P. Payoux and J. Ferreira
Adv Neurol, 2003, 91, 203-211.

2003 - 03 : Effects of a longitudinal training program on the metabolic and endocrine responses to exercise in fasted or fed overweight men
F. Crampes, F. Marion-Latard, A. Girard-Zakaroff, I. De Glisezinski, I. Harant, C. Thalamas, V. Stich, D. Riviere, M. Lafontan and M. Berlan
Obesity Research, 2003, 11, 2, 247-256.

2003 - 04 : Clinical and economic analysis of spa therapy in Parkinson’s disease
C. Brefel-Courbon, K. Desboeuf, C. Thalamas, M. Galitzky, J. M. Senard, O. Rascol and J. L. Montastruc
Mov Disord, 2003, 18, 5, 578-584.

2003 - 05 : Post exercise increase of lipid oxidation after a moderate exercise bout in untrined healthy obese men
F. Marion-Latard, F. Crampes, A. Girard-Zakaroff, I. De Glisezinski, I. Harant, V. Stich, C. Thalamas, D. Riviere, M. Lafontan and M. Berlan
Hormone and Metabolic Research, 2003, 35, 2, 97-103.

2003 - 06 : The pharmacokinetics and pharmacodynamics of intramuscular dermatan sulphate revisited.
S. Saivin, J. P. Cambus, C. Thalamas, G. LAU, B. Boneu, G. Houin and F. Gianese
Clin Drug Investigation, 2003, 23, 8, 533-543.

2003 - 07 : Cortical motor activation in akinetic schizophrenic patients : a pilot functional MRI study
P. Payoux, K. Boulanouar, C. Sarramon, N. Fabre, S. Descombes, M. Galitsky, C. Thalamas, C. Brefel-Courbon, U. Sabatini, C. Manelfe, F. Chollet, L. Schmitt and O. Rascol
Mov Disord, 2003, 19, 1, 83-90.

2003 - 08 : Efficacy of piribedil as early combination to L-dopa in patients with stable Parkinson’s disease. A 6-month randomised placebo-controlled study
M. Ziegler, A. Castro-Caldas, S. Del Signore and O. Rascol
Mov Disord, 2003, 18, 4, 418-425.

2003 - 09 : Mise en place d’une biothèque dans l’enquête de cohorte : E3N-EPIC
C. Guibout-Peigné, N. Prisse and F. Clavel-Chapelon
Rev Epidemiol Santé Publique, 2003, 51, 137-141.

2003 - 10 : Cardiac MIBG scintigraphy in a sensitive tool for detecting silent dysautonomic failure in Parkinson’s disease
F. Courbon, C. Brefel-Courbon, C. Thalamas, M. J. Alibelli, I. Berry, J. L. Montastruc, O. Rascol and J. M. Senard
Mov Disord, 2003, 18, 8, 890-897.

2003 - 11 : How much phenotypic variation can be attributed to parkin genotype ?
E. Lohmann, M. Periquet, V. Bonifati, N. W. Wood, G. De Michele, A. M. Bonnet, V. Fraix, E. Broussolle, M. W. I. M. Horstink, M. Vidailhet, P. Verpillat, T. Gasser, D. Nicholl, H. Teive, S. Raskin, O. Rascol, A. Destee, M. Ruberg, F. Gasparini, G. Meco, Y. Agid, A. Durr, A. Brice, F. P. s. D. G. S. Group and E. C. o. G. S. i. P. s. disease
Ann Neurol, 2003, 54, 2, 176-185.

2003 - 12 : The Unified Parkinson’s Disease Rating Scale (UPDRS) : status and recommendations
C. Goetz, W. Poewe, O. Rascol, C. Sampaio and S. G.T.
Mov Disord, 2003, 18, 7, 738-750.

2003 - 13 : Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis
M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R. A. Rudick, M. Kooijmans-Coutinho, M. Clanet, E. W. Radue and L. Kappos
Arch Neurol, 2003, 60, 12, 1736-9.

2003 - 14 : Slower progression of Parkinson’s disease with ropinirole versus L-dopa : the REAL-PET study
A. L. Whone, R. L. Watts, A. J. Stoessl, M. Davis, S. Reske, C. Nahmias, A. E. Lang, O. Rascol, M. J. Ribeiro, P. Remy, W. Poewe, R. A. Hauser and D. J. Brooks
Ann Neurol, 2003, 54, 1, 93-101.

2003 - 15 : Combien de noms de médicaments faut-il enseigner en pharmacologie dans les facultés de médecine ? Réflexions pédagogiques et propositions
J. L. Montastruc, O. Rascol, J. M. Senard, M. A. Tran, M. Berlan, C. Damase-Michel, M. Lapeyre-Mestre, C. Brefel-Courbon, H. Bagheri, A. Pathak and V. Claverie
La Lettre du Pharmacologue, 2003, 17, 3, 103-104.

2003 - 16 : Limitations of current Parkinson’s disease therapy
O. Rascol, P. Payoux, F. Ory, J. Ferreira, C. Brefel-Courbon and J. L. Montastruc
Ann Neurol, 2003, 53, suppl 3, S3-S15.

2003 - 17 : Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive logan graphical method in Parkinson’s disease
C. Prunier, P. Payoux, D. Guilloteau, S. Chalon, B. Giraudeau, C. Majorel, M. Tafani, E. Bezard, J. Esquerre and J. L. Baulieu
The Journal of Nuclear Medicine, 2003, 44, 5, 663-670.

2003 - 18 : Clinical-MRI correlations in the secondary progressive phase of MS : lessons from the treatment trials
M. Clanet, E. Cassol, C. Manelfe and I. Berry
J Neuro Sci, 2003, 206, 139-144.

2003 - 19 : Aerobic training improves exercise-induced lipolysis in SCAT and lipid utilization in overweight men
I. De Glisezinski, C. Moro, F. Pillard, F. Marion-Latard, I. Harant, M. Meste, M. Berlan, F. Crampes and D. Riviere
Am J Physiol Endocrinol Metab, 2003, 285, 5, E984-90.

2003 - 20 : Young-onset Parkinson disease with and without parkin gene mutations
S. Thobois, M. J. Ribeiro, E. Lohmann, A. Durr, P. Pollak, O. Rascol, S. Guillouet, E. Chapoy, N. Costes, Y. Agid, P. Remy, A. Brice and E. Broussolle
Arch Neurol, 2003, 60, May 2003, 713-718.

2003 - 21 : Hereditary ferritinopathy
R. Vidal, M. B. Delisle, O. Rascol and B. Ghetti
J Neurol Sci, 2003, 207, 110-111.

2003 - 22 : Correlation between motor recovery and intracerebral reorganization after subcortical infarcts
I. Loubinoux, C. Carel, J. Pariente, S. Dechaumont, J. F. Albucher, P. Marque, C. Manelfe and F. Chollet
Neuroimage, 2003, 20, 0, 2166-2180.

2003 - 23 : Neural substrates of impaired categorical perception of phonemes in adult dyslexics : an fMRI study
S. Ruff, N. Marie, P. Celsis, D. Cardebat and J. F. Demonet
Brain and Cognition, 2003, 53, 331-334.

2003 - 24 : Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization
J. M. Orgogozo, S. Gilman, J. F. Dartigues, B. Laurent, M. Puel, L. C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, B. F. Michel, M. Boada, A. Frank and C. Hock
Neurology, 2003, 61, 1, 46-54.

2004 - 01 : Alteration of amine oxidase activity in the adipose tissue of obese subjects
V. Visentin, E. Fontana, V. Durand de Saint Front, D. Prevot, M.-C. N., C. Thalamas, J. Galitzky, P. Valet and C. Carpéné Obesity Research, 2004, 12, 3, 1-9.

2004 - 02 : Clozapine improves dyskinesias in Parkinson’s disease. A double blind, placebo controlled study
F. Durif, B. Debilly, M. Galitzky, D. Morand, F. Viallet, M. Borg, S. Thobois, E. Broussolle and O. Rascol
Neurology, 2004, 62, 3, 381-388.

2004 - 03 : Le traitement médical de la maladie de Parkinson
O. Rascol
Les mouvements anormaux, 2004, 164-165.

2004 - 04 : Modulation of the transmission in group II heteronymous pathways by tizanidine in spastic hemiplegic patients
E. Maupas, P. Marque, C. F. Roques and M. Simonetta Moreau
J Neurol Neurosur Ps, 2004, 75, 130-135.

2004 - 05 : Atrial natriuretic peptide contributes to the physiological control of lipid mobilization in humans
C. Moro, F. Crampes, C. Sengenes, I. De Glisezinski, J. Galitzky, C. Thalamas, M. Lafontan and M. Berlan
Faseb J, 2004, 18, 7, 908-910.

2004 - 06 : Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide genre
R. Vidal, B. Ghetti, M. Takao, C. Brefel-Courbon, E. Uro-Coste, B. S. Glazier, V. Siani, M. D. Benson, P. Calvas, L. Miravalle, O. Rascol and M. B. Delisle
J Neuropath Exp Neur, 2004, 63, 4, 363-380.

2004 - 07 : Clozapine in drug-induced psychosis in PD : a randomized, placebo-controlled study with open follow-up
P. Pollak, F. Tison, O. Rascol, A. Destee, J. J. Pere, J. M. Senard, F. Durif, I. Bourdeix and o. b. o. t. F. C. P. S. Group
J Neurol Neurosurg Psychiatry, 2004, 75, 5, 689-695.

2004 - 08 : In vivo epinephrine-mediated regulation of gene expression in human skeletal muscle
N. Viguerie, K. Clement, P. Barbe, M. Courtine, A. Benis, D. Larrouy, B. Hanczar, V. Pelloux, C. Poitou, Y. Khalfallah, G. S. Barsh, C. Thalamas, J. Zucker and D. Langin
The Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5, 2000-2014.

2004 - 09 : Editorial : novel target genes for catecholamines in skeletal muscle
P. Arner
The Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5, 1998-1999.

2004 - 10 : New concerns about old drugs : valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance
O. Rascol, A. Pathak, H. Bagheri and J. L. Montastruc
Mov Disord, 2004, 19, 6, 611-613.

2004 - 11 : Multicenter, open-label, trial of Sarizotan in Parkinson’s disease patients with levodopa-induced dyskinesias (The SPLENDID study)
W. Olanow, P. Damier, C. Goetz, T. Mueller, J. G. Nutt, O. Rascol, A. Serbanescu, F. Decker and H. Russ
Clin Neuropharmacol, 2004, 27, 2, 58-62.

2004 - 12 : Crise de migraine et "générateur" du tronc cérébral : une étude en TEP. Résultats préliminaires.
M. Denuelle, N. Fabre, P. Payoux and G. Geraud
La Lettre du Neurologue, 2004, N° spécial, février 2004, 16-19.

2004 - 13 : Functional and pharmacological characterization of the natriuretic peptide-dependant lipolytic pathway in human fat cells
C. Moro, J. Galitzky, C. Sengenes, F. Crampes, M. Lafontan and M. Berlan
J Pharmacol Exp Ther, 2004, 308, 3, 984-992.

2004 - 14 : Subthalamic nucleus stimulation reduces abnormal motor cortical overactivity in Parkinson’s disease
P. Payoux, P. Remy, P. Damier, M. Miloudi, I. Loubinoux, B. Pidoux, V. Gaura, O. Rascol, Y. Samson and Y. Agid
Arch Neurol, 2004, 61, 1307-1313.

2004 - 15 : Genome-wide scan linkage analysis for Parkinson’s disease : the European genetic study of Parkinson’s disease
M. Martinez, A. Brice, J. R. Vaughan, A. Zimprich, M. M. Breteler, G. Meco, A. Filla, M. J. Farrer, C. Betard, J. Hardy, G. De Michele, V. Bonifati, B. Oostra, T. Gasser, N. W. Wood and A. Durr
J Med Genet, 2004, 41, 12, 900-7.

2004 - 16 : Movement disorder society task force report on the Hoehn and Yahr staging scale : status and recommendations
C. Goetz, W. Poewe, O. Rascol, C. Sampaio, G. T. Stebbins, C. Counsell, N. Giladi, R. G. Holloway, C. G. Moore, G. K. Wenning, M. D. Yahr and L. Seidl
Mov Disord, 2004, 19, 9, 1020-1028.

2004 - 17 : Levodopa in the treatment of Parkinson’s disease : current controversies
W. Olanow, Y. Agid, Y. Mizuno, A. Albanese, U. Bonucelli, P. Damier, J. De Yebenes, O. Gershanik, M. Guttman, F. Grandas, M. Hallett, O. Hornykiewicz, P. Jenner, R. Katzenschlager, W. J. Langston, P. Le Witt, E. Melamed, M. A. Mena, P. P. Michel, C. Mytilineou, J. A. Obeso, W. Poewe, N. P. Quinn, R. Raisman-Vozari, A. H. Rajput, O. Rascol, C. Sampaio and F. Stocchi
Mov Disord, 2004, 19, 9, 997-1005.

2004 - 18 : Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease
P. Ibanez, A. M. Bonnet, B. Debarges, E. Lohmann, F. Tison, P. Pollak, Y. Agid, A. Durr, A. Brice and F. P. s. D. G. S. Group
The Lancet, 2004, 364, Research letters, 1169-1171.

2004 - 19 : Valvulopathies cardiaques sous pergolide : le point aujourd’hui
J. L. Montastruc, A. Pathak, H. Bagheri and O. Rascol
La Lettre du Neurologue, 2004, 7, viii, 219-220.

2004 - 20 : Insulin detemir offers improved glycemic control compared with NPH insulin in people with type I diabetes : a randomized clinical trial
P. Home, P. Bartley, D. Russell-Jones, H. Hanaire-Broutin, J. E. Heeg, P. Abrams, M. Landin-Olsson, B. Hylleberg, H. Lang, E. Draeger and s. s. group
Diabetes Care, 2004, 27, 5, 1081-1087.

2004 - 21 : Atypical Parkinsonism and annonaceae consumption in New Caledonia. (letter to the Editor)
G. Angibaud, C. Gaultier and O. Rascol
Mov Disord, 2004, 19, 5, 603-604.

2004 - 22 : Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson’s disease patients : pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study
J. C. Zijlmans, B. Debilly, O. Rascol, A. Lees and F. Durif
Mov Disord, 2004, 19, 9, 1006-1011.

2004 - 23 : Interferon beta-1a in relapsing multiple sclerosis : four-year extension of the European IFNbeta-1a Dose-Comparison Study
M. Clanet, L. Kappos, H. P. Hartung and R. Hohlfeld
Mult Scler, 2004, 10, 2, 139-44.

2004 - 24 : Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)
G. K. Wenning, F. Tison, K. Seppi, C. Sampaio, A. Diem, F. Yekhlef, I. Ghorayeb, F. Ory, M. Galitzky, T. Scaravilli, M. Bozi, C. Colosimo, S. Gilman, C. W. Shults, N. P. Quinn, O. Rascol and W. Poewe
Mov Disord, 2004, 19, 12, 1391-402.

2004 - 25 : Neuroimaging in stroke recovery : a position paper from the first international workshop on neuroimaging and stroke recovery
J. C. Baron, S. E. Black, A. J. Butler, J. Carey, F. Chollet, L. G. Cohen, M. Corbetta, C. S.C., B. H. Dobkin, R. Frackowiak, W. D. Heiss, H. Johansen-erg, J. W. Krakauer, R. M. Lazar, L. L. Lennihan, I. Loubinoux, R. S. Marshall, P. Matthews, M. Mohr, G. Nelles, A. Pascual-Leone, V. Pomeroy, M. Rijntjes, P. M. Rossini, J. C. Rothwell, R. J. Seitz, S. L. Small, A. Sunderland, N. S. Ward, C. Weiller and R. J. S. Wise
Cerebrovascular Diseases, 2004, 18, 260-267,
2004 - 26 : A longitudinal fMRI study : in recovering and then in clinically stable sub-cortical stroke patients
D. Tombari, I. Loubinoux, J. Pariente, A. Gerdelat, J. F. Albucher, J. Tardy, E. Cassol and F. Chollet
Neuroimage, 2004, 23, 3, 827-39.

2004 - 27 : Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women
E. Arvidsson, N. Viguerie, I. Andersson, C. Verdich, D. Langin and P. Arner
Diabetes, 2004, 53, 8, 1966-71.

2004 - 28 : [Biomarkers as prognostic factors in pulmonary arterial hypertension. Rationale and study design] J. L. Cracowski, A. Yaici, O. Sitbon, M. Reynaud-Gaubert, J. C. Renversez, C. Pison, P. Faure, C. Cracowski, N. Chouri, A. Chaouat, F. Chabot, E. Schwedhelm, R. Maas, B. Degano, J. F. Mornex and M. Humbert
Rev Mal Respir, 2004, 21, 6 Pt 1, 1137-43.

2005 - 01 : Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, lasting effectin adjunct therapy with Rasagiline given once daily, study) : a randomised, double-blind, parallel-group trial
O. Rascol, D. J. Brooks, E. Melamed, W. H. Oertel, W. Poewe, F. Stocchi and E. Tolosa
The Lancet, 2005, 365, 947-954,
2005 - 02 : Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial
S. Gilman, M. Koller, R. S. Black, L. Jenkins, S. G. Griffith, N. C. Fox, L. Eisner, L. C. Kirby, M. Boada Rovira, F. Forette and J. M. Orgogozo
Neurology, 2005, 64, 9, 1553-1562.

2005 - 03 : Modafinil for fatigue in MS : a randomized placebo-controlled double-blind study
B. Stankoff, E. Waubant, C. Confavreux, G. Edan, M. Debouverie, L. Rumbach, T. Moreau, J. Pelletier, C. Lubetzki and M. Clanet
Neurology, 2005, 64, 7, 1139-43.

2005 - 04 : Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a
M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R. A. Rudick, M. Kooijmans, M. Clanet, E. W. Radue and L. Kappos
Neurology, 2005, 64, 2, 236-40.

2005 - 05 : Adipose tissue gene expression in obese subjects during low-fat and high-fat hypocaloric diets
N. Viguerie, H. Vidal, P. Arner, C. Holst, C. Verdich, S. Avizou, A. Astrup, W. H. Saris, I. A. Macdonald, E. Klimcakova, K. Clement, A. Martinez, J. Hoffstedt, T. I. Sorensen and D. Langin
Diabetologia, 2005, 48, 1, 123-31.

2005 - 06 : Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer
I. Loubinoux, D. Tombari, J. Pariente, A. Gerdelat-Mas, X. Franceries, E. Cassol, O. Rascol, J. Pastor and F. Chollet
Neuroimage, 2005, 27, 2, 299-313.

2005 - 07 : The effect of tau genotype on clinical features in FTDP-17
Y. Baba, Y. Tsubio, M. Baker, R. J. Uitti, M. Hutton, D. W. Dickson, M. J. Farrer, J. D. Putzke, B. K. Woodruff, B. Ghetti, J. R. Murrell, B. F. Boeve, M. Petersen, P. Verpillat, A. Brice, M. B. Delisle, O. Rascol, K. Arima, M. Dysken, M. Yasuda, T. Kobayashi, N. Sunohara, O. Komure, S. Kuno, A. D. Sperfeld, G. Stoppe, J. Kohlhase, S. Pickering-Brown, D. Neary, O. Bugiani and Z. K. Wszolek
Parkinsonism and related disorders, 2005, 11, 205-208.

2005 - 08 : The specific thromboxane receptor antagonist S18886 : pharmacokinetic and pharmacodynamic studies
P. Gaussem, J. L. Reny, C. Thalamas, N. Chatelain, M. Kroumova, B. Jude, B. Boneu and J. N. Fiessinger
J Thromb Haemostasis, 2005, 3, 1437-1445.

2005 - 09 : Long-haul flights do not activate hemostasis in young healthy men
H. Boccalon, B. Boneu, J. Emmerich, C. Thalamas and J. B. Ruidavets
J Thromb Haemost, 2005, 3, 7, 1539-41.

2005 - 10 : Pergolide : Multiple-Dose Pharmacokinetics in Patients with Mild to Moderate Parkinson Disease
C. Thalamas, I. Rajman, J. Kulisevsky, A. Lledo, A. E. Mackie, O. Blin, T. A. Gillespie, M. Seger and O. Rascol
Clin Neuropharmacol, 2005, 28, 3, 120-125.

2005 - 11 : Comparison of two physical activity questionnaires in obese subjects : the NUGENOB study
B. Tehard, W. H. Saris, A. Astrup, J. A. Martinez, M. A. Taylor, P. Barbe, B. Richterova, B. Guy-Grand, T. I. Sorensen and J. M. Oppert
Med Sci Sports Exerc, 2005, 37, 9, 1535-41.

2005 - 12 : Training enhances ANP lipid-mobilizing action in adipose tissue of overweight men
C. Moro, F. Pillard, I. De Glisezinski, I. Harant, D. Riviere, V. Stich, M. Lafontan, F. Crampes and M. Berlan
Med Sci Sports Exerc, 2005, 37, 7, 1126-32.

2005 - 13 : Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers
Y. Cadroy, C. Thalamas, K. Sakariassen and B. Boneu
Thromb Research, 2005, 116, 293-300.

2005 - 14 : Transdermal delivery of dopaminergic agents
O. Rascol
Neurology, 2005, 65, 2 Suppl 1, S1-2.

2005 - 15 : The European Multiple System Atrophy-Study Group (EMSA-SG)
F. Geser, K. Seppi, M. Stampfer-Kountchev, M. Kollensperger, A. Diem, J. P. Ndayisaba, K. Ostergaard, E. Dupont, A. Cardozo, E. Tolosa, M. Abele, R. Dodel, T. Klockgether, I. Ghorayeb, F. Yekhlef, F. Tison, C. Daniels, F. Kopper, G. Deuschl, M. Coelho, J. Ferreira, M. M. Rosa, C. Sampaio, M. Bozi, A. Schrag, J. Hooker, H. Kim, T. Scaravilli, C. J. Mathias, C. Fowler, N. Wood, N. Quinn, H. Widner, C. F. Nilsson, O. Lindvall, N. Schimke, K. M. Eggert, W. Oertel, F. del Sorbo, F. Carella, A. Albanese, M. T. Pellecchia, P. Barone, R. Djaldetti, G. Meco, C. Colosimo, A. Gonzalez-Mandly, J. Berciano, T. Gurevich, N. Giladi, M. Galitzky, F. Ory, O. Rascol, C. Kamm, K. Buerk, S. Maass, T. Gasser, W. Poewe and G. K. Wenning
J Neural Transm, 2005, 112, 12, 1677-86.

2005 - 16 : [Cardiac cellular therapy : from cells to the first clinical uses] J. Roncalli, B. Leobon, P. Massabuau, M. Galinier, A. Parini, A. Pathak, P. Bourin, A. A. Hagege, P. Menasche, G. Fournial and J. M. Fauvel
Arch Mal Coeur Vaiss, 2005, 98, 6, 637-48.

2005 - 17 : Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects
A. Gerdelat-Mas, I. Loubinoux, D. Tombari, O. Rascol, F. Chollet and M. Simonetta-Moreau
Neuroimage, 2005, 27, 2, 314-22.

2005 - 18 : Effect of levodopa on pain threshold in Parkinson’s disease : a clinical and positron emission tomography study
C. Brefel-Courbon, P. Payoux, C. Thalamas, F. Ory, I. Quelven, F. Chollet, J. L. Montastruc and O. Rascol
Mov Disord, 2005, 20, 12, 1557-63.

2005 - 19 : [Positron emission tomographic studies of migraine] G. Geraud, M. Denuelle, N. Fabre, P. Payoux and F. Chollet
Rev Neurol (Paris), 2005, 161, 6-7, 666-70.

2005 - 21 : Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
N. C. Fox, R. S. Black, S. Gilman, M. N. Rossor, S. G. Griffith, L. Jenkins and M. Koller
Neurology, 2005, 64, 9, 1563-72.

2005 - 22 : Trimetazidine : a new cause for drug-induced Parkinsonism ?
A. Sommet, C. Azaïs-Vuillemin, H. Bagheri, O. Rascol and J. L. Montastruc
Mov Disord, 2005, 20, 8, 1081.

2005 - 23 : Evidence-based medical review update : pharmacological and surgical treatments of Parkinson’s disease : 2001 to 2004
C. G. Goetz, W. Poewe, O. Rascol and C. Sampaio
Mov Disord, 2005, 20, 5, 523-39.

2005 - 24 : Rasagiline in the pharmacotherapy of Parkinson’s disease - a review
O. Rascol
Expert Opin Pharmacother, 2005, 6, 12, 2061-75.

2005 - 25 : Assessing the risk of a necessary harm : placebo surgery in Parkinson disease
O. Rascol
Neurology, 2005, 65, 7, 982-3.

2005 - 26 : Neutralizing antibodies and efficacy of interferon beta-1a : a 4-year controlled study
L. Kappos, M. Clanet, M. Sandberg-Wollheim, E. W. Radue, H. P. Hartung, R. Hohlfeld, J. Xu, D. Bennett, A. Sandrock and S. Goelz
Neurology, 2005, 65, 1, 40-7.

2005 - 27 : [Natriuretic peptides : a new lipolytic pathway in human fat cells] C. Sengenes, C. Moro, J. Galitzky, M. Berlan and M. Lafontan
Med Sci (Paris), 2005, 21, 1, 61-5.

2006 - 01 : Sleep disruption, daytime somnolence and "sleep attacks" in Parkinson’s disease : a clinical survey in Parkinson’s disease patients and age-matched healthy volunteers
J. Ferreira, K. Desboeuf, M. Galitzky, C. Thalamas, C. Brefel-Courbon, N. Fabre, J. M. Senard, J. L. Montastruc, C. Sampaio and O. Rascol
Eur J Neurol, 2006, 13, 209-214.

2006 - 02 : Randomized, multi-center trial of two hypo-energetic diets in obese subjects : high- versus low-fat content
M. Petersen, M. A. Taylor, W. H. Saris, C. Verdich, S. Toubro, I. Macdonald, S. Rossner, V. Stich, B. Guy-Grand, D. Langin, J. A. Martinez, O. Pedersen, C. Holst, T. I. Sorensen and A. Astrup
Int J Obes (Lond), 2006, 30, 3, 552-60.

2006 - 03 : Fat oxidation before and after a high fat load in the obese insulin-resistant state
E. E. Blaak, G. Hul, C. Verdich, V. Stich, A. Martinez, M. Petersen, E. F. Feskens, K. Patel, J. M. Oppert, P. Barbe, S. Toubro, I. Anderson, J. Polak, A. Astrup, I. A. Macdonald, D. Langin, C. Holst, T. I. Sorensen and W. H. Saris
J Clin Endocrinol Metab, 2006, 91, 4, 1462-9.

2006 - 04 : Lack of inhibitory interaction between somatosensory afferent inputs and intracortical inhibitory interneurons in focal hand dystonia
M. Simonetta-Moreau, G. Lourenco, S. Sangla, L. Mazieres, M. Vidailhet and S. Meunier
Mov Disord, 2006, Mar 10,
2006 - 05 : Methylphenidate modulates cerebral post-stroke reorganization
J. Tardy, J. Pariente, A. Leger, S. Dechaumont-Palacin, A. Gerdelat, V. Guiraud, F. Conchou, J. F. Albucher, P. Marque, X. Franceries, C. Cognard, O. Rascol, F. Chollet and I. Loubinoux
Neuroimage, 2006, 33, 913-922.

2006 - 06 : Genetic Polymorphisms and Weight Loss in Obesity : A Randomised Trial of Hypo-Energetic High- versus Low-Fat Diets
T. I. Sorensen, P. Boutin, M. A. Taylor, L. H. Larsen, C. Verdich, L. Petersen, C. Holst, S. M. Echwald, C. Dina, S. Toubro, M. Petersen, J. Polak, K. Clement, J. A. Martinez, D. Langin, J. M. Oppert, V. Stich, I. Macdonald, P. Arner, W. H. Saris, O. Pedersen, A. Astrup and P. Froguel
PLoS Clin Trials, 2006, 1, 2, e12.

2006 - 07 : Cerebral autoregulation is preserved in multiple system atrophy : A transcranial Doppler study
A. Pavy-Le Traon, R. L. Hughson, C. Thalamas, M. Galitsky, N. Fabre, O. Rascol and J. M. Senard
Mov Disord, 2006, 21, 12, 2122-6.

2006 - 08 : High-dose atorvastatin after stroke or transient ischemic attack
P. Amarenco, J. Bogousslavsky, A. Callahan, 3rd, L. B. Goldstein, M. Hennerici, A. E. Rudolph, H. Sillesen, L. Simunovic, M. Szarek, K. M. Welch and J. A. Zivin
N Engl J Med, 2006, 355, 6, 549-59.

2006 - 09 : Early piribedil monotherapy of Parkinson’s disease : A planned seven-month report of the REGAIN study
O. Rascol, B. Dubois, A. C. Caldas, S. Senn, S. Del Signore and A. Lees
Mov Disord, 2006,
2006 - 10 : Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I : early (uncomplicated) Parkinson’s disease
M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol and C. Sampaio
Eur J Neurol, 2006, 13, 11, 1170-85.

2006 - 11 : Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II : late (complicated) Parkinson’s disease
M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol and C. Sampaio
Eur J Neurol, 2006, 13, 11, 1186-202.

2006 - 12 : Ergoline and non-ergoline derivatives in the treatment of Parkinson’s disease
H. Reichmann, A. Bilsing, R. Ehret, W. Greulich, J. B. Schulz, S. A. and O. Rascol
J Neurol, 2006, 253, suppl 4, IV/36-IV/38.

2006 - 13 : Chapitre 1 : Historique de la maladie de Parkinson : l’exemple des médicaments antiparkinsoniens modernes
O. Rascol
Les 10 points clés sur la stimulation cérébrale profonde dans la maladie de Parkinson, 2006, 5-14.

2006 - 14 : Clinical studies with ropinirole in Parkinson’s disease and RLS
W. H. Jost, D. Angersbach and O. Rascol
J Neurol, 2006, The dopaminergic system : an everlasting challenge. supplement 253, suppl 4, IV/16-IV/21.

2006 - 15 : Development of dyskinesias in a 5-year trial of ropinirole and L-dopa
O. Rascol, D. J. Brooks, A. D. Korczyn, P. P. De Deyn, C. E. Clarke, A. E. Lang and M. Abdalla
Mov Disord, 2006, 21, 11, 1844-1850.

2006 - 16 : Disease-modifying strategies in Parkinson’s disease
C. Sampaio and O. Rascol
Parkinson’s disease and movement disorders, 2006, Fifth Edition,
2006 - 17 : Experimental therapeutics of Parkinson’s disease and the development of new symptomatic medicines for Parkinson’s disease
O. Rascol and C. Sampaio
Parkinson’s disease and movement disorders, 2006, Fifth Edition,
2006 - 18 : Disease modifying trials in Alzheimer disease : methodological and statistical issues
S. Andrieu, O. Rascol, T. Lang, H. Grandjean and B. Vellas
J Nutr Health Aging, 2006, 10, 2, 116-7.

2006 - 19 : Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia
P. Damier
Arch Gen Psychiat, 2006, 64, 170-176.

2007 - 01 : Impaired fat-induced thermogenesis in obese subjects : the NUGENOB study
E. E. Blaak, G. Hul, C. Verdich, V. Stich, J. A. Martinez, M. Petersen, E. F. Feskens, K. Patel, J. M. Oppert, P. Barbe, S. Toubro, J. Polak, I. Anderson, A. Astrup, I. Macdonald, D. Langin, T. Sorensen and W. H. Saris
Obesity (Silver Spring), 2007, 15, 3, 653-63.

2007 - 02 : Disease modifying trials in Alzheimer’s disease : a European Task Force Consensus
B. Vellas, S. Andrieu, C. Sampaio, G. Wilcock and f. t. E. T. F. Group
Lancet, 2007, 6, 56-62.

2007 - 03 : Efficacy of Pramipexole and transdermal Rotigotine in advances Parkinson’s disease : a double-blind, double-dummy, randomized trial
O. Rascol, E. Tolosa, N. P. Quinn, E. Martignoni, W. Oertel and W. Poewe
Lancet, 2007, 6, 513-520.

2007 - 04 : Movement Disorder Society-Sponsored Revions of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) : Process, Format, and Clinimetric Testing Plan
C. Goetz, S. Fahn, P. Martinez-Martin, W. Poewe, C. Sampaio, G. T. Stebbins, M. B. Stern, B. C. Tilley, R. Dodel, B. Dubois, R. G. Holloway, J. Jankovic, J. Kulisevsky, A. E. Lang, A. Lees, S. Leurgans, P. Le Witt, D. Nyenhuis, W. Olanow, O. Rascol, A. E. Schrag, J. Teresi, B. Van Hilten and N. LaPelle
Mov Disord, 2007, 22, 1, 41-47.

2007 - 05 : Sarizotan as a treatment for dyskinesias in Parkinson’s disease : a double-blind placebo controlled trial
C. Goetz, P. Damier, C. Hicking, E. Laska, T. Muller, W. Olanow, O. Rascol and H. Russ
Mov Disord, 2007, 22, 2, 179-186.

2007 - 06 : Levodopa raises objective pain threshold in Parkinson’s disease : A RIII reflex study
A. Gerdelat-Mas, M. Simonetta-Moreau, C. Thalamas, F. Ory-Magne, T. Slaoui, O. Rascol and C. Brefel-Courbon
J Neurol Neurosurg Psychiatry, 2007, 78, 1140-1142.

2007 - 07 : Safety and tolerability of growth hormone therapy in multiple system atrophy : a double-blind, placebo-controlled study
B. Holmberg, J. O. Johansson, W. Poewe, G. K. Wenning, N. P. Quinn, C. J. Mathias, E. Tolosa, A. Cardozo, N. Dizdar, O. Rascol and T. Slaoui
Mov Disord, 2007, 22, 8, 1138-1144.

2007 - 08 : Depression rating scales in Parkinson’s disease : critique and recommendations
A. E. Schrag, P. Barone, R. G. Brown, A. F. Leentjens, W. M. McDonald, S. Starkstein, D. Weintraub, W. Poewe, O. Rascol, C. Sampaio, G. T. Stebbins and C. G. Goetz
Mov Disord, 2007, 22, 8, 1077-1092.

2007 - 09 : Passage de l’entacapone à la tolcapone : étude multicentrique en double aveugle, randomisée, contre traitement de référence, dans la maladie de Parkinson avancée
I. E. P. d. l. e. à. l. tolcapone
Mov Dis, 2007, 22, 1, 14-19.

2007 - 10 : Atrial Natriuretic Peptide contribution to lipid mobilization and utilization during head-down bed rest in man
C. Moro, F. Pillard, I. de Glisezinski, F. Crampes, C. Thalamas, I. Harant, M. A. Marques, M. Lafontan and M. Berlan
Am J Physiol Regul Integr Comp Physiol, 2007, 293, 612-617.

2007 - 11 : Does ageing influence deep brain stimulation outcomes in Parkinson’s disease ?
F. Ory-Magne, C. Brefel-Courbon, M. Simonetta-Moreau, N. Fabre, J. A. Lotterie, P. Chaynes, I. Berry, Y. Lazorthes and O. Rascol
Mov Dis, 2007, 10, 1457-1463.

2007 - 12 : Dopamine agonists
O. Rascol, T. Slaoui, W. Regragui, F. Ory-Magne, C. Brefel-Courbon and J. L. Montastruc
Handbook of Clinical Neurology, 2007, 84, 73-92.

2007 - 13 : Sex differences in lipolysis-reglating mechanisms in overweight subjects : effect of exercise intensity
C. Moro, F. Pillard, I. De Glisezinski, F. Crampes, C. Thalamas, I. Harant, M. A. Marques, M. Lafontan and M. Berlan
Obesity, 2007, 15, 9, 2245-2255.

2007 - 14 : Lipid oxidation according to intensity and exercise duration in overweight men and women
F. Pillard, C. Moro, I. Harant, E. Garrigue, M. Lafontan, M. Berlan, F. Crampes, I. De Glisezinski and D. Riviere
Obesity, 2007, 15, 9, 2256-2262.

2007 - 15 : Riluzole in Huntington’s disease : a 3-year, randomized controlled study
G. B. Landwehrmeyer, B. Dubois, J. Garcia de Yénenes, B. Kremer, W. Gaus, P. H. Kraus, H. Przuntek, M. Dib, A. Doble, W. Fischer, A. C. Ludolph and E. H. s. d. i. s. group
Ann Neurol, 2007, 62, 3, 262-272.

2007 - 16 : Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease
H. Ollat, B. Laurent, S. Bakchine, B. F. Michel, J. Touchon and B. Dubois
Encephale, 2007, 32, 2, 211-215.

2007 - 17 : La lévodopa modifie les seuils nociceptifs chez le patient parkinsonien
T. Slaoui, A. Mas-Gerdelat, F. Ory-Magne, O. Rascol and C. Brefel-Courbon
Rev Neurol, 2007, 163, 1, 66-71.

2007 - 18 : Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa
R. A. Hauser, O. Rascol, A. D. Korczyn, A. Jon Stoessl, R. L. Watts, W. Poewe, P. P. De Deyn and A. E. Lang
Mov Dis, 2007, 22, 16, 2409-2417.

2007 - 19 : Rotigotine transdermal patch in early Parkinson’s disease : A randomized, double-blind, controlled study versus placebo and ropinirole
N. Giladi, B. Boroojerdi, A. D. Korczyn, D. J. Burn, C. E. Clarke and A. H. Schapira
Mov Disord, 2007, 22, 16, 2398-404.

2008 - 01 : Relationship between weight, levodopa and dyskinesia : the significance of levodopa dose per kilogram body weight
J. C. Sharma, I. N. Ross, O. Rascol and D. Brooks
Eur J of Neurol, 2008, Journal compilation 2008 EFNS,
2008 - 02 : Cascade of levodopa dose and weight-related dyskinesia in Parkinson’s disease (LD-WD-PD) cascade
J. C. Sharma, L. Macnamara, M. Hasoon, M. Vassallo and O. Rascol
Parkinsonism and Related Disorders, 2008, 12, 499-505.